749902-11-2 Usage
Uses
Used in Pharmaceutical Research:
2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE is used as a reagent for the synthesis of various heterocyclic compounds, which are essential in the development of new pharmaceuticals. Its unique structure allows it to be a building block in the creation of diverse therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE is utilized as a key intermediate, facilitating the production of a wide range of chemical compounds with potential applications in various industries.
Used in Medicinal Chemistry:
2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE is employed as a component in the design and synthesis of novel drug candidates, leveraging its ability to modulate biological pathways for therapeutic benefits.
Used in Drug Discovery:
2-(3-METHOXY-PHENYL)-THIAZOLE-4-CARBALDEHYDE is used as a starting material in drug discovery processes, where its properties are explored for potential medicinal applications, including the treatment of various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 749902-11-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,4,9,9,0 and 2 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 749902-11:
(8*7)+(7*4)+(6*9)+(5*9)+(4*0)+(3*2)+(2*1)+(1*1)=192
192 % 10 = 2
So 749902-11-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H9NO2S/c1-14-10-4-2-3-8(5-10)11-12-9(6-13)7-15-11/h2-7H,1H3
749902-11-2Relevant academic research and scientific papers
Bataille, Carole J.R.,Brennan, Méabh B.,Byrne, Simon,Davies, Stephen G.,Durbin, Matthew,Fedorov, Oleg,Huber, Kilian V.M.,Jones, Alan M.,Knapp, Stefan,Liu, Gu,Nadali, Anna,Quevedo, Camilo E.,Russell, Angela J.,Walker, Roderick G.,Westwood, Robert,Wynne, Graham M.
, p. 2657 - 2665 (2017)
The PIM family of serine/threonine kinases have become an attractive target for anti-cancer drug development, particularly for certain hematological malignancies. Here, we describe the discovery of a series of inhibitors of the PIM kinase family using a high throughput screening strategy. Through a combination of molecular modeling and optimization studies, the intrinsic potencies and molecular properties of this series of compounds was significantly improved. An excellent pan-PIM isoform inhibition profile was observed across the series, while optimized examples show good selectivity over other kinases. Two PIM-expressing leukemic cancer cell lines, MV4-11 and K562, were employed to evaluate the in vitro anti-proliferative effects of selected inhibitors. Encouraging activities were observed for many examples, with the best example (44) giving an IC50 of 0.75 μM against the K562 cell line. These data provide a promising starting point for further development of this series as a new cancer therapy through PIM kinase inhibition.
